Showing 101 - 120 results of 18,016 for search '(( significantly ((a decrease) OR (nn decrease)) ) OR ( significantly mediate decrease ))', query time: 0.64s Refine Results
  1. 101
  2. 102
  3. 103
  4. 104
  5. 105
  6. 106
  7. 107
  8. 108
  9. 109
  10. 110
  11. 111
  12. 112
  13. 113
  14. 114
  15. 115
  16. 116

    Active DNA Demethylation Mediated by <i>OsGADD45a2</i> Regulates Growth, Development, and Blast (Magnaporthe oryzea) Resistance in Rice by Ganghua Zhou (9283406)

    Published 2024
    “…In <i>OsGADD45a2</i> overexpression lines, significant decreases in CG and CHG methylation levels were observed in protein-coding genes, leading to their upregulation. …”
  17. 117

    Data Sheet 1_Increasing donor kidney age significantly aggravates the negative effect of pretransplant donor-specific anti-HLA antibodies on kidney graft survival.pdf by Michiel G. H. Betjes (8407413)

    Published 2025
    “…For comparison, recipients aged ≥65 years of a deceased donor kidney aged <65 years had an uncensored 1- and 3-year graft survival of 92% and 78%, respectively, without preDSA, and if transplanted with preDSA, this decreased to 77% and 69%, respectively.…”
  18. 118
  19. 119

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  20. 120

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”